Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2000

View Archived Issues

Stimulation of brain reward areas by nicotine causes addiction

KS Biomedix forms collaboration with Eukarion

Serono to develop protein expression technology with Modex Therapeutics

Alendronate markedly reduces fracture risk in women with osteoporosis

Dietary changes affect homocysteine levels and possibly the risk of heart disease

Potential human pheromone receptor gene identified

Tobramycin shows promise in clinical study of bronchiectasis

Gliatech-Guilford merger terminated

Bayer announces large cerivastatin trial in acute MI

Randomized trial of cardiac resynchronization shows positive results

BioTime seeks European approval of Hextend

Simulect shows good results in pediatric transplant recipients

BioTransplant reports positive phase I/II results for BTI-322 in liver transplant patients

Zometa approved in Canada for treatment of tumor-induced hypercalcemia

Lung imaging agent from Nycomed Amersham enters phase I trial

FXR ligands synthesized by Glaxo Wellcome

NexMed presents results of topical alprostadil treatment

NIDDK reports design of GPCR ligands

Donor intestine irradiation improves survival

BioTransplant breeds miniswine without human-tropic PERV

Aventis reports MMP-12 inhibitors for the treament of emphysema in smokers

New anti-HIV compounds disclosed in patent literature by HHS

Asthma research at Bayer targets inhibition of MMP

New series of factor Xa inhibitors reported by German lab

Fujisawa continues research into treatments for urinary incontinence

New developments in neurological research at AstraZeneca

Anxiolytic and antidepressant compounds with a dual mechanism of action

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...